ES2333069T3 - Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante. - Google Patents
Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante. Download PDFInfo
- Publication number
- ES2333069T3 ES2333069T3 ES98912919T ES98912919T ES2333069T3 ES 2333069 T3 ES2333069 T3 ES 2333069T3 ES 98912919 T ES98912919 T ES 98912919T ES 98912919 T ES98912919 T ES 98912919T ES 2333069 T3 ES2333069 T3 ES 2333069T3
- Authority
- ES
- Spain
- Prior art keywords
- cpg
- alum
- dna
- hbsag
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 47
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 39
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 39
- 108091029430 CpG site Proteins 0.000 title claims abstract description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title 1
- 229910052782 aluminium Inorganic materials 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 38
- 230000028993 immune response Effects 0.000 claims abstract description 28
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 230000000890 antigenic effect Effects 0.000 claims abstract description 22
- 230000001404 mediated effect Effects 0.000 claims abstract description 4
- 229940037003 alum Drugs 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 241000700721 Hepatitis B virus Species 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 230000004044 response Effects 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 14
- 230000006698 induction Effects 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 230000036039 immunity Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 28
- 230000003612 virological effect Effects 0.000 abstract description 8
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 106
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 61
- 108020004414 DNA Proteins 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 51
- 239000002671 adjuvant Substances 0.000 description 49
- 108010041986 DNA Vaccines Proteins 0.000 description 40
- 229940021995 DNA vaccine Drugs 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 229940031626 subunit vaccine Drugs 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 210000003719 b-lymphocyte Anatomy 0.000 description 16
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 14
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 230000008348 humoral response Effects 0.000 description 12
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- -1 phosphorothioate modified oligonucleotides Chemical class 0.000 description 5
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 101710132601 Capsid protein Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940023143 protein vaccine Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000013638 trimer Substances 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000749 chronicity Toxicity 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000030933 DNA methylation on cytosine Effects 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000005737 synergistic response Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Chemical group O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Chemical group O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- BOKOVLFWCAFYHP-UHFFFAOYSA-N dihydroxy-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound COP(O)(O)=S BOKOVLFWCAFYHP-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Seasonings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4037697P | 1997-03-10 | 1997-03-10 | |
| US40376P | 1997-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2333069T3 true ES2333069T3 (es) | 2010-02-16 |
Family
ID=21910655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98912919T Expired - Lifetime ES2333069T3 (es) | 1997-03-10 | 1998-03-10 | Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante. |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2172216A3 (https=) |
| JP (2) | JP5087758B2 (https=) |
| AT (1) | ATE441432T1 (https=) |
| AU (1) | AU753688B2 (https=) |
| CA (1) | CA2283557A1 (https=) |
| DE (1) | DE69841122D1 (https=) |
| DK (1) | DK1005368T3 (https=) |
| ES (1) | ES2333069T3 (https=) |
| PT (1) | PT1005368E (https=) |
| WO (1) | WO1998040100A1 (https=) |
Families Citing this family (292)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1997025429A1 (en) | 1996-01-04 | 1997-07-17 | Rican Limited | Helicobacter pylori bacterioferritin |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| PT991403E (pt) | 1997-01-30 | 2003-08-29 | Chiron Corp | Uso de microparticulas com antigenio adsorvido para estimular respostas imunes |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| WO1998055495A2 (en) | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US7138384B1 (en) | 1997-08-29 | 2006-11-21 | The Regents Of The University Of California | Modulators of DNA cytosine-5 methyltransferase and methods for use thereof |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| EP1079824B1 (en) | 1998-05-19 | 2011-08-31 | RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) | Triterpene compositions and methods for use thereof |
| PT1077722E (pt) | 1998-05-22 | 2006-12-29 | Coley Pharm Group Inc | Produtos e composições para utilização na indução da imunidade mucosal |
| US7049302B1 (en) | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| FR2783170B1 (fr) * | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
| US6887464B1 (en) | 1999-02-02 | 2005-05-03 | Biocache Pharmaceuticals, Inc. | Advanced antigen presentation platform |
| JP2003517452A (ja) * | 1999-02-05 | 2003-05-27 | アルク−アベル・アー／エス | 新規粘膜デリバリーシステム |
| US8206749B1 (en) | 1999-02-26 | 2012-06-26 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
| JP4812942B2 (ja) * | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強 |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| WO2000067023A1 (en) * | 1999-04-29 | 2000-11-09 | Coley Pharmaceutical Gmbh | Screening for immunostimulatory dna functional modifyers |
| US6737066B1 (en) | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
| WO2000067787A2 (en) * | 1999-05-06 | 2000-11-16 | The Immune Response Corporation | Hiv immunogenic compositions and methods |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
| CA2380947C (en) | 1999-08-19 | 2011-11-01 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| CZ20021029A3 (cs) * | 1999-08-27 | 2002-08-14 | Inex Pharmaceuticals Corp. | Kompozice a její pouľití pro stimulaci sekrece cytokinů a indukci imunitní odpovědi |
| GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| SK287400B6 (sk) * | 1999-09-25 | 2010-08-09 | University Of Iowa Research Foundation | Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| EP1322655B1 (en) | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| EP1950296B1 (en) * | 2000-01-14 | 2014-05-07 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| EP1311288A1 (en) * | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20020107212A1 (en) * | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
| US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
| CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| AU2001270134B2 (en) * | 2000-06-22 | 2006-06-15 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| JP2005500806A (ja) | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス |
| DK1328543T3 (da) | 2000-10-27 | 2009-11-23 | Novartis Vaccines & Diagnostic | Nukleinsyrer og proteiner fra streptococcus-gruppe A & B |
| ATE398175T1 (de) | 2000-12-08 | 2008-07-15 | Coley Pharmaceuticals Gmbh | Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung |
| JP4188687B2 (ja) | 2000-12-27 | 2008-11-26 | ダイナバックス テクノロジーズ コーポレイション | 免疫変調ポリヌクレオチド及びその使用法 |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| JP4188092B2 (ja) | 2001-05-21 | 2008-11-26 | インターツェル・アクチェンゲゼルシャフト | 免疫促進性オリゴデオキシ核酸分子 |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| CA2451974C (en) | 2001-06-21 | 2014-10-14 | Karen L. Fearon | Chimeric immunomodulatory compounds and methods of using the same |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| JP4607452B2 (ja) | 2001-08-07 | 2011-01-05 | ダイナバックス テクノロジーズ コーポレイション | 免疫調節性組成物、製剤およびその使用方法 |
| WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
| PT1567641E (pt) | 2001-08-24 | 2012-08-21 | Uvic Industry Partnerships Inc | Proaerolisina contendo sequência de activação de proteases e métodos de uso para o tratamento do cancro da próstata |
| AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| WO2004012669A2 (en) | 2002-08-01 | 2004-02-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
| US7514414B2 (en) | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| JP2005508945A (ja) * | 2001-10-06 | 2005-04-07 | メリアル リミテッド | Ｃｐｇ配合物及び関連方法 |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| CA2471092A1 (en) | 2001-12-21 | 2003-07-10 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| EP1474432A1 (en) * | 2002-02-04 | 2004-11-10 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| EP2572707A3 (en) | 2002-02-20 | 2013-11-06 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
| PL215263B1 (pl) | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| CA2477675C (en) | 2002-03-05 | 2013-05-21 | Ramot At Tel-Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein |
| US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| SI1524994T1 (sl) | 2002-07-19 | 2011-08-31 | Cytos Biotechnology Ag | Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe |
| CA2484941A1 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| EP2402026A3 (en) | 2002-09-13 | 2012-04-18 | Intercell AG | Method for isolating hepatitis C virus peptides |
| US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| EP1562982B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| PT1992635E (pt) | 2002-12-23 | 2012-03-20 | Dynavax Tech Corp | Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos |
| AU2003299994A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| ES2461350T3 (es) | 2003-01-30 | 2014-05-19 | Novartis Ag | Vacunas inyectables contra múltiples serogrupos de meningococos |
| WO2004074454A2 (en) | 2003-02-20 | 2004-09-02 | University Of Connecticut Health Center | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| ATE485056T1 (de) | 2003-03-24 | 2010-11-15 | Intercell Ag | Verbesserte impfstoffe |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| EP1605972A2 (en) * | 2003-03-26 | 2005-12-21 | Cytos Biotechnology AG | Hiv-peptide-carrier-conjugates |
| ES2529736T3 (es) | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| SI1633189T1 (sl) | 2003-05-19 | 2017-12-29 | Prothena Biosciences Limited | Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc |
| EP1631264B8 (en) | 2003-06-02 | 2017-05-24 | GlaxoSmithKline Biologicals SA | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| JP2007505147A (ja) | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | 単純ヘルペスウイルス感染の治療および予防用ワクチン |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| CN103357002A (zh) | 2003-10-02 | 2013-10-23 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
| WO2005107797A1 (en) | 2004-03-09 | 2005-11-17 | Chiron Corporation | Influenza virus vaccines |
| US7820175B2 (en) | 2004-03-19 | 2010-10-26 | Herbal Spring, Llc | Herbal therapy for the treatment of food allergy |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| ATE512670T1 (de) | 2004-04-30 | 2011-07-15 | Novartis Vaccines & Diagnostic | Meningokokken-konjugat-impfung |
| CN1989439B (zh) | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | 治疗葡萄膜炎的方法以及组合物 |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| US20090104226A1 (en) | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| US9573979B2 (en) | 2004-09-24 | 2017-02-21 | Susanne Modrow | Modified VP1-capsid protein of parvovirus B19 |
| US7780963B2 (en) | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| US9809824B2 (en) | 2004-12-13 | 2017-11-07 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
| ES2616294T3 (es) | 2005-01-27 | 2017-06-12 | Children's Hospital & Research Center At Oakland | Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis |
| CN100485034C (zh) * | 2005-01-28 | 2009-05-06 | 权滢周 | 从分支杆菌中提取的用于刺激免疫功能，治疗免疫相关性疾病，过敏性皮炎和/或保护正常免疫细胞的寡核苷酸 |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| AU2006214064B2 (en) | 2005-02-18 | 2012-04-26 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| JP2008535862A (ja) | 2005-04-08 | 2008-09-04 | キメリクス，インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
| JP2008536515A (ja) | 2005-04-18 | 2008-09-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現 |
| EP1891093B1 (en) | 2005-06-14 | 2011-03-23 | Protox Therapeutics Incorporated | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
| WO2007004977A1 (en) | 2005-07-01 | 2007-01-11 | Index Pharmaceuticals Ab | Immunostimulatory method |
| PL2179737T3 (pl) | 2005-07-01 | 2014-01-31 | Index Pharmaceuticals Ab | Sposób do modulowania wrażliwości na steroidy |
| CA2615626A1 (en) | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
| CA2626253A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
| CA2625969A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| ES2420829T3 (es) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
| CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| EP3753574A1 (en) | 2006-01-27 | 2020-12-23 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
| US20070224205A1 (en) | 2006-03-07 | 2007-09-27 | Powell Thomas J | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2004226A1 (en) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
| US20100285062A1 (en) | 2006-03-31 | 2010-11-11 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| WO2007119815A1 (ja) | 2006-04-14 | 2007-10-25 | Kyowa Hakko Kirin Co., Ltd. | Ｔｏｌｌ様受容体９作動薬 |
| US8357781B2 (en) | 2006-06-01 | 2013-01-22 | Janssen Alzheimer Immunotherapy | Neuroactive fragments of APP |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| ES2536401T3 (es) | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| HUE025225T2 (en) | 2007-02-23 | 2016-02-29 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic diseases |
| EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| CA2699513C (en) | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| EP3067048B1 (en) | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Compositions for inducing immune responses |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| PL2235046T3 (pl) | 2007-12-21 | 2012-12-31 | Novartis Ag | Zmutowane formy streptolizyny O |
| DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
| ES2557282T3 (es) | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso |
| WO2009115917A2 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
| WO2009128949A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of dengue viral proteins and methods of use |
| WO2009143292A2 (en) | 2008-05-21 | 2009-11-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
| MX2010014026A (es) | 2008-06-27 | 2011-02-15 | Pfizer | Composiciones adyuvantes novedosas. |
| NZ591768A (en) | 2008-09-18 | 2012-11-30 | Novartis Ag | Vaccine adjuvant combinations |
| KR101413844B1 (ko) | 2008-12-09 | 2014-06-30 | 화이자 백신스 엘엘씨 | ＩｇＥ ＣＨ３ 펩티드 백신 |
| CN102481349B (zh) | 2009-01-12 | 2014-10-15 | 诺华股份有限公司 | 抗革兰氏阳性细菌疫苗中的Cna_B结构域 |
| WO2010092479A2 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
| CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
| HUE049695T2 (hu) | 2009-03-24 | 2020-10-28 | Glaxosmithkline Biologicals Sa | Adjuváló H meningococcus faktort kötõ fehérje |
| AU2010232490B2 (en) | 2009-04-03 | 2016-08-11 | Agenus Inc. | Methods for preparing and using multichaperone-antigen complexes |
| MX2011010735A (es) | 2009-04-14 | 2012-01-25 | Novartis Ag | Composiciones para inmunizacion contra staphylococcus aureus. |
| CA2762653A1 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
| WO2010146414A1 (en) | 2009-06-15 | 2010-12-23 | National University Of Singapore | Influenza vaccine, composition, and methods of use |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| PL2464658T3 (pl) | 2009-07-16 | 2015-03-31 | Novartis Ag | Immunogeny z Escherichia coli o zniesionej toksyczności |
| NZ598356A (en) | 2009-07-30 | 2014-06-27 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| US20110076300A1 (en) | 2009-08-27 | 2011-03-31 | Mariagrazia Pizza | Hybrid Polypeptides Including Meningococcal fHBP Sequences |
| CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
| PE20161551A1 (es) | 2009-09-03 | 2017-01-18 | Pfizer Vaccines Llc | Vacuna de pcsk9 |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
| GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
| US8974799B2 (en) | 2009-09-30 | 2015-03-10 | Novartis Ag | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| CN102724988B (zh) | 2009-09-30 | 2014-09-10 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽的表达 |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| CA2779816A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| US20130034573A1 (en) | 2009-12-22 | 2013-02-07 | Celldex Therapeutics, Inc. | Vaccine compositions |
| US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| CN102802662A (zh) | 2010-03-18 | 2012-11-28 | 诺华有限公司 | 用于脑膜炎球菌血清组b的含佐剂疫苗 |
| ES2910199T3 (es) | 2010-03-30 | 2022-05-11 | Childrens Hospital & Res Center At Oakland | Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| BR112012025364A2 (pt) | 2010-04-07 | 2015-09-22 | Novartis Ag | método para geração de partícula semelhante a vírus de parvovírus b19 |
| WO2011130379A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| EP2576613A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Inc. | Her-2 peptides and vaccines |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| AU2011276328C1 (en) | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| CA2805414C (en) | 2010-07-14 | 2020-07-07 | Merck Sharp & Dohme Corp. | Anti-addl monoclonal antibody and uses thereof |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
| WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| AU2012211278B2 (en) | 2011-01-26 | 2016-11-10 | Glaxosmithkline Biologicals Sa | RSV immunization regimen |
| US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| DK2707385T3 (da) | 2011-05-13 | 2017-11-20 | Glaxosmithkline Biologicals Sa | RSV-F-præfusionsantigener |
| KR102052215B1 (ko) | 2011-06-01 | 2019-12-04 | 야누스 바이오테라퓨틱스, 인크. | 신규한 면역 시스템 조절제 |
| WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| WO2013009564A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Tyrosine ligation process |
| US10030052B2 (en) | 2011-07-25 | 2018-07-24 | Glaxosmithkline Biologicals Sa | Parvovirus Vp1 unique region polypeptides and compositions thereof |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| EP2755683B1 (en) | 2011-09-14 | 2019-04-03 | GlaxoSmithKline Biologicals SA | Methods for making saccharide-protein glycoconjugates |
| WO2013038385A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Escherichia coli vaccine combination |
| WO2013052550A2 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| EP2776069A1 (en) | 2011-11-07 | 2014-09-17 | Novartis AG | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| AU2012349753A1 (en) | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| US12268718B2 (en) | 2012-01-16 | 2025-04-08 | Labyrinth Holdings Llc | Control of cellular redox levels |
| SG11201402650RA (en) | 2012-01-16 | 2014-06-27 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| RU2014138418A (ru) | 2012-02-24 | 2016-04-10 | Новартис Аг | Белки пилей и композиции |
| US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
| CN104321078A (zh) | 2012-04-26 | 2015-01-28 | 诺华股份有限公司 | 抗原和抗原组合 |
| US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
| AU2013255511B2 (en) | 2012-05-04 | 2016-01-28 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| WO2013174832A1 (en) | 2012-05-22 | 2013-11-28 | Novartis Ag | Meningococcus serogroup x conjugate |
| US20150140068A1 (en) | 2012-07-06 | 2015-05-21 | Novartis Ag | Immunogenic compositions and uses thereof |
| US9764027B2 (en) | 2012-09-18 | 2017-09-19 | Glaxosmithkline Biologicals Sa | Outer membrane vesicles |
| BR112015006264A2 (pt) | 2012-09-21 | 2017-07-04 | Mckenna Elizabeth | composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas |
| AR092897A1 (es) | 2012-10-03 | 2015-05-06 | Novartis Ag | Composiciones inmunogenicas |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| JP6494527B2 (ja) | 2013-02-07 | 2019-04-03 | ザ チルドレンズ メディカル センター コーポレーション | 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| CN105188741A (zh) | 2013-04-03 | 2015-12-23 | 阿勒丁医疗公司 | 新型纳米颗粒组合物 |
| JP2016520077A (ja) | 2013-05-15 | 2016-07-11 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| EP3033106A1 (en) * | 2013-08-14 | 2016-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Immunoadjuvant compositions and uses thereof |
| KR101943171B1 (ko) | 2013-09-19 | 2019-01-29 | 조에티스 서비시즈 엘엘씨 | 유성 아쥬반트 |
| JP2016535989A (ja) | 2013-11-01 | 2016-11-24 | ファイザー・インク | 前立腺関連抗原を発現させるためのベクター |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| EP3071974A2 (en) | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| BE1022857A1 (fr) | 2014-03-26 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Immunisation contre staphylococcus aureus |
| EP3398948A3 (en) | 2014-08-22 | 2018-12-05 | Janus Biotherapeutics, Inc. | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| DK3244920T5 (da) | 2015-01-16 | 2024-10-07 | Zoetis Services Llc | Mund- og klovsyge-vaccine |
| SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
| HK1254344A1 (zh) | 2015-06-26 | 2019-07-19 | Seqirus UK Limited | 抗原匹配的流感疫苗 |
| EP4480544A3 (en) | 2015-08-25 | 2025-03-26 | Babita Agrawal | Immunomodulatory compositions andmethods of use thereof |
| WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| CA3000313A1 (en) | 2015-10-08 | 2017-04-13 | The Governors Of The University Of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| TWI709647B (zh) | 2016-01-19 | 2020-11-11 | 美商輝瑞股份有限公司 | 癌症疫苗 |
| WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| KR102625114B1 (ko) | 2017-09-28 | 2024-01-12 | 화이자 인코포레이티드 | 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법 |
| US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3946444A1 (en) | 2019-04-01 | 2022-02-09 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
| CN115175924A (zh) | 2020-02-26 | 2022-10-11 | 港大科桥有限公司 | 基于pd-1的针对冠状病毒感染的疫苗 |
| WO2021236809A2 (en) | 2020-05-19 | 2021-11-25 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of alzheimer's disease |
| EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| CA3183994A1 (en) | 2020-06-24 | 2021-12-30 | Philip James Dolan Iii | Antibodies recognizing sortilin |
| KR20230080397A (ko) | 2020-08-07 | 2023-06-07 | 오타이르 프로테나 리미티드 | 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신 |
| WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
| JPWO2022196701A1 (https=) | 2021-03-16 | 2022-09-22 | ||
| EP4310095A4 (en) | 2021-03-16 | 2025-07-23 | Univ Osaka | SARS-CoV-2 VIRUS-SPECIFIC FOLLICULAR HELPER T CELLS (TFH) |
| US20250161295A1 (en) | 2022-04-15 | 2025-05-22 | Yale University | Exatecan formulation |
| CN116064554A (zh) * | 2022-08-09 | 2023-05-05 | 常州市第三人民医院 | 一种具有免疫调节功能的核酸序列、应用及抗病毒药物 |
| IL320955A (en) | 2022-12-13 | 2025-07-01 | Pfizer | Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE |
| WO2025059508A1 (en) | 2023-09-15 | 2025-03-20 | Prothena Biosciences Limited | Compositions and methods of reducing immunogenicity and improving stability of antibodies |
| WO2025238502A1 (en) | 2024-05-14 | 2025-11-20 | Pfizer Inc. | Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof |
| WO2025257712A1 (en) | 2024-06-12 | 2025-12-18 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| WO1983001451A1 (en) | 1981-10-23 | 1983-04-28 | Molecular Biosystems Inc | Oligonucleotide therapeutic agent and methods of making same |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE509102T1 (de) * | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| EP0879284B1 (en) * | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| WO1997040163A1 (en) * | 1996-04-19 | 1997-10-30 | Metin Colpan | Nucleic acid vaccination for parvoviral infections |
| ES2241042T3 (es) * | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
| EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
-
1998
- 1998-03-10 AU AU67595/98A patent/AU753688B2/en not_active Ceased
- 1998-03-10 JP JP53973098A patent/JP5087758B2/ja not_active Expired - Fee Related
- 1998-03-10 AT AT98912919T patent/ATE441432T1/de active
- 1998-03-10 EP EP20090166906 patent/EP2172216A3/en not_active Withdrawn
- 1998-03-10 ES ES98912919T patent/ES2333069T3/es not_active Expired - Lifetime
- 1998-03-10 CA CA 2283557 patent/CA2283557A1/en not_active Abandoned
- 1998-03-10 DE DE69841122T patent/DE69841122D1/de not_active Expired - Lifetime
- 1998-03-10 EP EP98912919A patent/EP1005368B1/en not_active Expired - Lifetime
- 1998-03-10 PT PT98912919T patent/PT1005368E/pt unknown
- 1998-03-10 DK DK98912919T patent/DK1005368T3/da active
- 1998-03-10 WO PCT/US1998/004703 patent/WO1998040100A1/en not_active Ceased
-
2009
- 2009-08-06 JP JP2009183917A patent/JP2009280606A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP5087758B2 (ja) | 2012-12-05 |
| WO1998040100A1 (en) | 1998-09-17 |
| JP2002511841A (ja) | 2002-04-16 |
| JP2009280606A (ja) | 2009-12-03 |
| AU6759598A (en) | 1998-09-29 |
| DK1005368T3 (da) | 2010-01-04 |
| EP2172216A2 (en) | 2010-04-07 |
| PT1005368E (pt) | 2009-11-19 |
| EP1005368A1 (en) | 2000-06-07 |
| EP2172216A3 (en) | 2010-11-24 |
| EP1005368A4 (en) | 2004-09-29 |
| EP1005368B1 (en) | 2009-09-02 |
| CA2283557A1 (en) | 1998-09-17 |
| AU753688B2 (en) | 2002-10-24 |
| DE69841122D1 (de) | 2009-10-15 |
| ATE441432T1 (de) | 2009-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2333069T3 (es) | Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante. | |
| WO1998040100A9 (en) | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT | |
| ES2628744T3 (es) | Métodos y productos para inducir inmunidad en mucosas | |
| Klinman | CpG DNA as a vaccine adjuvant | |
| Klinman et al. | Use of CpG oligodeoxynucleotides as immune adjuvants | |
| ES2257068T3 (es) | Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas. | |
| JP2023506441A (ja) | 医薬組成物及びその用途 | |
| WO2006056142A1 (en) | Cpg single-strand deoxynucleotides for use as adjuvant | |
| CN115252772A (zh) | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 | |
| AU2005216075B2 (en) | Potent mucosal immune response induced by modified immunomodulatory oligonucleotides | |
| TW202202623A (zh) | 治療和預防冠狀病毒之成分和方法 | |
| Dory et al. | CpG motif in ATCGAT hexamer improves DNA-vaccine efficiency against lethal Pseudorabies virus infection in pigs | |
| US20040191214A1 (en) | Nucleoside vaccine adjuvants | |
| ES2386369T3 (es) | Vacunas que comprenden la proteína de núcleo HBC truncado mas adyuvantes basados en saponina | |
| HK1143062A (en) | Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant | |
| EA051416B1 (ru) | Применение искусственно синтезированного одноцепочечного cpg-дезоксиолигонуклеотида в вакцинах | |
| WO2024186780A2 (en) | Compositions and methods for treating and preventing crimean congo hemorrhagic fever virus | |
| JP2013510189A (ja) | 非ｄｎａ塩基含有ポリヌクレオチド組成物、および免疫応答の調節のためのそれらの使用 | |
| WO2025119932A1 (en) | Nucleic acid construct comprising nucleic acid sequences encoding immunogenic peptides derived from zika virus | |
| AU2021214939A1 (en) | Compositions and methods for treating and preventing hepatitis B and D | |
| Ulmer et al. | DNA vaccines: immunogenicity and preclinical efficacy | |
| MXPA04003867A (es) | Uso de la timosina para aumentar la inmunizacion genetica y composiciones farmaceuticas inmunologicas a base de timosina. | |
| WO2002011761A2 (en) | Vaccine against rsv | |
| ULMER | E. Delivery Systems and Adjuvants |